Excessive Daytime Sleepiness Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Suven LifeSciences, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, NLS Pharma, XWPharma, Takeda

DelveInsight's "Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Excessive Daytime Sleepiness, historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Excessive Daytime Sleepiness market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Excessive Daytime Sleepiness Market Forecast
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Excessive Daytime Sleepiness Market Report:
• The Excessive Daytime Sleepiness market size was valued approximately USD 6,227 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the therapeutic market for Excessive Daytime Sleepiness in the United States was valued at USD 4.69 billion.
• The existing Excessive Daytime Sleepiness market is primarily dominated by SUNOSI, WAKIX, XYREM, XYWAV, and other therapies. In 2023, the market size for XYREM and WAKIX was USD 1,163 million and USD 565 million, respectively, across the 7MM.
• In 2023, there were approximately 7 million diagnosed prevalent cases of excessive daytime sleepiness across the 7MM, with this number expected to grow throughout the study period (2020-2034) due to the increasing prevalence of related conditions.
• DelveInsight's estimates indicate that in 2023, there were approximately 3.9 million diagnosed prevalent cases of excessive daytime sleepiness in the United States, with this number anticipated to increase by 2034.
• According to our epidemiology analysis, there were approximately 2 million diagnosed prevalent cases of excessive daytime sleepiness across the EU4 and the UK in 2023. Germany had the highest number of diagnosed cases, followed by France.
• In 2023, Japan represented about 16% of the diagnosed prevalent population for excessive daytime sleepiness within the 7MM.
• In 2023, Japan generated approximately USD 382.8 million in revenue from the Excessive Daytime Sleepiness market, with this figure expected to rise by 2034.
• Key Excessive Daytime Sleepiness Companies: Bioprojet Pharma/Harmony Biosciences, Jazz Pharmaceuticals, Axsome Therapeutic, Suven LifeSciences, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, NLS Pharma, XWPharma, Takeda, and others
• Key Excessive Daytime Sleepiness Therapies: WAKIX/ OZAWADE (pitolisant), SUNOSI (Solriamfetol), AXS-12 (Reboxetine), SUVN-G3031, FT218, AXS-12, THN102, Samelisant, Quilience, XW10172, TAK-994, and others
• The Excessive Daytime Sleepiness epidemiology based diagnosed prevalent cases analyzed that in the US, the majority of the cases of EDS are found in OSA and Bipolar disorder, followed by Parkinson's Disease, Narcolepsy, and Idiopathic Hypersomnia
• The Excessive Daytime Sleepiness market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Excessive Daytime Sleepiness pipeline products will significantly revolutionize the Excessive Daytime Sleepiness market dynamics.

Excessive Daytime Sleepiness Overview
The condition known as excessive daytime sleepiness (EDS) is characterised by difficulty remaining awake and alert during the day's main waking periods, with sleep happening accidentally or at inopportune times.

Get a Free sample for the Excessive Daytime Sleepiness Market Report:
https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Excessive Daytime Sleepiness Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Excessive Daytime Sleepiness Epidemiology Segmentation:
The Excessive Daytime Sleepiness market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Excessive Daytime Sleepiness
• Prevalent Cases of Excessive Daytime Sleepiness by severity
• Gender-specific Prevalence of Excessive Daytime Sleepiness
• Diagnosed Cases of Episodic and Chronic Excessive Daytime Sleepiness

Download the report to understand which factors are driving Excessive Daytime Sleepiness epidemiology trends @ Excessive Daytime Sleepiness Epidemiology Forecast
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Excessive Daytime Sleepiness Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to get launched during the study period. The analysis covers Excessive Daytime Sleepiness market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Excessive Daytime Sleepiness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Excessive Daytime Sleepiness Therapies and Key Companies
• WAKIX/ OZAWADE (pitolisant): Bioprojet Pharma/Harmony Biosciences
• SUNOSI (Solriamfetol): Jazz Pharmaceuticals.
• AXS-12 (Reboxetine): Axsome Therapeutic
• SUVN-G3031: Suven LifeSciences
• FT218: Avadel Pharmaceutical
• AXS-12: Axsome Therapeutic
• THN102: Theranexus
• Samelisant: Suven Life Sciences
• Quilience: NLS Pharma
• XW10172: XWPharma
• TAK-994: Takeda

Discover more about therapies set to grab major Excessive Daytime Sleepiness market share @ Excessive Daytime Sleepiness Treatment Market
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Excessive Daytime Sleepiness Market Drivers
• Robust clinical pipeline
• Support of the US FDA by granting designations
• Recent launch of Xywav and Ozawade
• Increasing prevalence dueto appearance of EDS as asymptom in various disorders

Excessive Daytime Sleepiness Market Barriers
• High cost of therapies
• Delay in diagnosis
• A limited number of participants
• Lack of practical measurement tools in diagnosis

Scope of the Excessive Daytime Sleepiness Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Excessive Daytime Sleepiness Companies: Bioprojet Pharma/Harmony Biosciences, Jazz Pharmaceuticals, Axsome Therapeutic, Suven LifeSciences, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, NLS Pharma, XWPharma, Takeda, and others
• Key Excessive Daytime Sleepiness Therapies: WAKIX/ OZAWADE (pitolisant), SUNOSI (Solriamfetol), AXS-12 (Reboxetine), SUVN-G3031, FT218, AXS-12, THN102, Samelisant, Quilience, XW10172, TAK-994, and others
• Excessive Daytime Sleepiness Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and Excessive Daytime Sleepiness emerging therapies
• Excessive Daytime Sleepiness Market Dynamics: Excessive Daytime Sleepiness market drivers and Excessive Daytime Sleepiness market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Excessive Daytime Sleepiness Unmet Needs, KOL's views, Analyst's views, Excessive Daytime Sleepiness Market Access and Reimbursement

To know more about Excessive Daytime Sleepiness companies working in the treatment market, visit @ Excessive Daytime Sleepiness Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Excessive Daytime Sleepiness Market Report Introduction
2. Executive Summary for Excessive Daytime Sleepiness
3. SWOT analysis of Excessive Daytime Sleepiness
4. Excessive Daytime Sleepiness Patient Share (%) Overview at a Glance
5. Excessive Daytime Sleepiness Market Overview at a Glance
6. Excessive Daytime Sleepiness Disease Background and Overview
7. Excessive Daytime Sleepiness Epidemiology and Patient Population
8. Country-Specific Patient Population of Excessive Daytime Sleepiness
9. Excessive Daytime Sleepiness Current Treatment and Medical Practices
10. Excessive Daytime Sleepiness Unmet Needs
11. Excessive Daytime Sleepiness Emerging Therapies
12. Excessive Daytime Sleepiness Market Outlook
13. Country-Wise Excessive Daytime Sleepiness Market Analysis (2020-2034)
14. Excessive Daytime Sleepiness Market Access and Reimbursement of Therapies
15. Excessive Daytime Sleepiness Market Drivers
16. Excessive Daytime Sleepiness Market Barriers
17. Excessive Daytime Sleepiness Appendix
18. Excessive Daytime Sleepiness Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports:

Cart-related Neurotoxicity Market https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
DelveInsight's "CART-related Neurotoxicity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CART-related Neurotoxicity, historical and forecasted epidemiology as well as the CART-related Neurotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

H3n2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
DelveInsight's "H3N2 Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the H3N2 Infection, historical and forecasted epidemiology as well as the H3N2 Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.